These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Biochemical markers of types I and III collagen and limited joint mobility in type 1 diabetic patients. Arkkila PE; Koskinen PJ; Kantola IM; Rönnemaa T; Seppänen E; Viikari JS Acta Diabetol; 2003 Dec; 40(4):151-5. PubMed ID: 14740273 [TBL] [Abstract][Full Text] [Related]
23. Effects of a 4-month recruit training program on markers of bone metabolism. Evans RK; Antczak AJ; Lester M; Yanovich R; Israeli E; Moran DS Med Sci Sports Exerc; 2008 Nov; 40(11 Suppl):S660-70. PubMed ID: 18849868 [TBL] [Abstract][Full Text] [Related]
24. [Biochemical markers of bone turnover. New aspect. An automated assay for measuring bone turnover markers]. Miura M Clin Calcium; 2009 Aug; 19(8):1160-9. PubMed ID: 19638700 [TBL] [Abstract][Full Text] [Related]
25. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation. Tziakas DN; Chalikias GK; Papanas N; Stakos DA; Chatzikyriakou SV; Maltezos E Europace; 2007 Aug; 9(8):589-96. PubMed ID: 17485436 [TBL] [Abstract][Full Text] [Related]
26. Short-term response of bone turnover to low-dose oral contraceptives in exercising women with hypothalamic amenorrhea. Vescovi JD; VanHeest JL; De Souza MJ Contraception; 2008 Feb; 77(2):97-104. PubMed ID: 18226672 [TBL] [Abstract][Full Text] [Related]
27. [Collagen synthesis and heart failure]. Jiménez-Navarro MF; Gómez-Doblas JJ; Cabrera-Bueno F; Cruz-Ocaña E; Rodríguez-Bailón I; Ruiz-Galdón M; Morell M; Molero E; de Teresa-Galván E Rev Esp Cardiol; 2005 Aug; 58(8):975-8. PubMed ID: 16053832 [TBL] [Abstract][Full Text] [Related]
28. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331 [TBL] [Abstract][Full Text] [Related]
29. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement of PICP and PINP in the evaluation of pharmaceutical treatment efficacy for osteoporosis]. Nakatsuka K; Nishizawa Y; Miura M Clin Calcium; 2006 Jun; 16(6):977-85. PubMed ID: 16751694 [TBL] [Abstract][Full Text] [Related]
30. Levels of biochemical bone marker procollagen type I N-propeptide (PINP) in Thai women aged 40-70 years. Boonyanurak P; Wilawan K J Med Assoc Thai; 2009 Jul; 92(7):873-7. PubMed ID: 19626803 [TBL] [Abstract][Full Text] [Related]
31. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538 [TBL] [Abstract][Full Text] [Related]
32. The heritability of optic disc parameters: a classic twin study. Healey P; Carbonaro F; Taylor B; Spector TD; Mitchell P; Hammond CJ Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):77-80. PubMed ID: 18172077 [TBL] [Abstract][Full Text] [Related]
33. Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects. Huda MS; Durham BH; Wong SP; Dovey TM; McCulloch P; Kerrigan D; Pinkney JH; Fraser WD; Wilding JP Bone; 2007 Sep; 41(3):406-13. PubMed ID: 17613297 [TBL] [Abstract][Full Text] [Related]
34. [N-terminal propeptide of type I procollagen (PINP)]. Sone T; Fukunaga M Nihon Rinsho; 2004 Dec; 62 Suppl 12():232-5. PubMed ID: 15658307 [No Abstract] [Full Text] [Related]
35. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial. Pullerits R; d'Elia HF; Tarkowski A; Carlsten H Rheumatology (Oxford); 2009 Jul; 48(7):785-90. PubMed ID: 19416946 [TBL] [Abstract][Full Text] [Related]
36. [Biochemical markers of bone turnover. New aspect. Bone metabolic markers in prostatic carcinoma]. Kuroda I; Ueno M Clin Calcium; 2009 Aug; 19(8):1170-7. PubMed ID: 19638701 [TBL] [Abstract][Full Text] [Related]
37. Anthropometrics and biochemical markers in men. Donescu OS; Battié MC; Videman T; Risteli J; Eyre D J Clin Densitom; 2005; 8(2):222-7. PubMed ID: 15908711 [TBL] [Abstract][Full Text] [Related]
38. The efficacy of the bone markers osteocalcin and the carboxyterminal cross-linked telopeptide of type-I collagen in evaluating osteogenesis in a canine crural lengthening model. Theyse LF; Mol JA; Voorhout G; Terlou M; Hazewinkel HA Vet J; 2006 May; 171(3):525-31. PubMed ID: 16624720 [TBL] [Abstract][Full Text] [Related]
39. Development of a highly sensitive, high-throughput, mass spectrometry-based assay for rat procollagen type-I N-terminal propeptide (PINP) to measure bone formation activity. Han B; Copeland M; Geiser AG; Hale LV; Harvey A; Ma YL; Powers CS; Sato M; You J; Hale JE J Proteome Res; 2007 Nov; 6(11):4218-29. PubMed ID: 17924680 [TBL] [Abstract][Full Text] [Related]
40. [Dynamics of bone biochemical markers in nephrotic children treated with prednisone and metabolites of vitamin D]. Wojnar J; Roszkowska-Blaim M; Pańczyk-Tomaszewska M Przegl Lek; 2007; 64(9):552-8. PubMed ID: 18510075 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]